Navigation Links
Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research

lopment of rBChE."

Dr. Langermann continued, "These recent data suggest a promising new potential therapeutic application for rBChE, which we intend to explore further. Our next steps, in collaboration with Dr. Soreq and her group, will include evaluating rBChE in animal models of Alzheimer's disease. If the results continue to be encouraging, then it would allow us to expand applications of rBChE therapy to areas other than nerve agent toxicity resulting in broader commercial applications with important benefits to society."

The work conducted under the Alzheimer's research program is based on a patent owned by Yissum (the technology transfer company of The Hebrew University of Jerusalem), entitled "Human BChE Variants as Protectors from Amyloid Diseases", which has been licensed to PharmAthene.

About Protexia(r): Recombinant Human Butyrylcholinesterase (rBChE)

Protexia is a form of recombinant human butyrylcholinesterase (rBChE), a potent organophosphorus (OP) scavenger protein produced in the milk of transgenic goats, which is being developed for use as a prophylactic against acute organophosphorus (OP) nerve agent toxicity.


Preclinical research conducted by PharmAthene's development partners, the US Army Medical Research Institute of Chemical Defence (USAMRICD) and DRDC Suffield, Defence Research and Development Canada, have demonstrated the capability of Protexia to protect laboratory animals from the toxic effects of chemical nerve agents.

In these studies, pre-treatment with rBChE provided 100% survival against the nerve agents VX and soman. In post-exposure therapeutic studies, administration of rBChE following nerve agent exposure resulted in enhanced survival compared to control animals.

While the utility of BChE to protect against nerve agent exposure is well documented, a major limitation in its development has been the inability to produce it in commercial volumes due to limited raw material availa
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
4. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
5. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
6. Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. CuraGen Presents Update on Clinical Development Program for Belinostat
9. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
10. Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
11. OXiGENE Abstracts Published in ASCO Program
Post Your Comments:
(Date:12/17/2014)... -- Strategic Health Services, Inc. (SHS), a leading provider of ... agreement with QualCare, Inc., a leading provider of health plans ... marketplace.  This agreement will further QualCare,s population health management ... brings to its clients in New Jersey ... QualCare plans cover more than 800,000 member lives, with ...
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
(Date:12/17/2014)... Ga. and RALEIGH, N.C. ... Trial Marketing Communications, LLC (CTMC), and Integrated Clinical ... patient recruitment and retention for clinical trials announce ... Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS will ... retention services to pharmaceutical, biotechnology and medical device ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... France and SWIFTWATER, Pa., June 16 Sanofi,Pasteur, the ... donate 60 million doses of H5N1 vaccine to the ... of an H5N1 vaccine,global stockpile., "The H5N1 virus ... the world and an outbreak of pandemic influenza would ...
... Results presented at the 90th annual Endocrine Society meeting show,significant ... ... painful intercourse, ANN ARBOR, Mich, June 16 QuatRx ... 3 clinical,trial of Ophena(TM) (ospemifene tablets) to treat postmenopausal women ...
Cached Medicine Technology:Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 2Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 3Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 4Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile 5Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 2Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 3Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 4
(Date:12/19/2014)... 2014 Today, Balfleet.com , a ... announces its formal dress promotion. All the old and ... 60% off. , Balfleet.com is well-known for its high ... prom dresses, cocktail dresses and more. Its formal dresses ... guarantee, and they can create an elegant look when ...
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... OK (PRWEB) December 19, 2014 Eufaula, ... home to Lake Eufaula, the state’s largest lake with ... lakeside town is home to a little more than ... 1:00 P.M. on Saturday, the 6th of December. , ... its way through downtown Eufaula on Main Street. ...
(Date:12/19/2014)... December 20, 2014 The print component ... and Business subscription of the Toronto Star, with a ... of 622,169. The digital component is distributed nationally through ... of top news sites and partner outlets. To explore ... . , The publication features an exclusive interview ...
(Date:12/19/2014)... 2014 (HealthDay News) -- Potentially illness-causing E. coli bacteria ... farmers markets, according to a new study. Researchers ... from 13 farmers markets in Los Angeles and Orange ... of almost 150 samples tested, 24 percent were positive ... according to the researchers. Both types of bacteria ...
Breaking Medicine News(10 mins):Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... their opinion- Nature’s way is far superior to pre-planned caesarian ... of it being unnecessary. , According to their ... encountered by a woman who opts for a C-section, in ... higher than that of a woman undergoing natural delivery. ...
... Researchers at UT Southwestern Medical Center have found that ... ,"We have discovered that C-Reactive Protein (CRP) ... hypertension, it actually induces hypertension," said Dr. Wanpen Vongpatanasin, ... the study appearing in the February issue of Circulation. ...
... PhD, published the first results showing that a biological phenomenon ... Since then he has used RNAi gene therapy to effectively ... mice. ,With three human RNAi gene therapy trials ... in RSV pneumonia - the technique Kay pioneered may be ...
... By first probing the way primitive yeast make ... long-sought protein whose human// counterpart controls cholesterol production ... study by investigators at Johns Hopkins University School ... Lilly Co., was published in the February issue ...
... Diabetes case management that takes a patient’s specific ... and decrease the incidence of diabetes-related complications over ... ,"Better management results in reduced long-term complications, ... said lead researcher Todd Gilmer, Ph.D. ...
... Jumping on a garden trampoline is a fun form of ... for children and youths// than traffic, according to a new ... of concern "especially due to neck and head injuries" that ... northern Sweden told the Svenska Dagbladet newspaper. ,The ...
Cached Medicine News:Health News:C-Reactive Protein Induces Hypertension 2Health News:RNAi Shows Promise in Gene Therapy 2Health News:Primitive Yeast Yields Secrets Of Human Cholesterol And Drug Metabolism 2Health News:Culturally Specific Diabetes Management Helps Low-Income Patients 2
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
The ACMI™ Operative Laparoscopy System is designed for single- and dual-incision CO2 laser procedures and is used with 45cm laparoscopic instruments....
The edge-to-edge clarity of the laparoscopes provides excellent image definition.Even small structures are easily recognized due to the optimal depth of focus. The outstanding optical quality provide...
Stryker bariatric laparoscopes set the standard in picture quality....
Medicine Products: